Close Menu

NEW YORK – Clinical-stage oncology company AnHeart Therapeutics said on Monday that the Chinese drug evaluation agency has granted investigational new drug authorization to its lead candidate taletrectinib, allowing it to start two Phase II trials in the next few months.

Taletrectinib is a ROS1 and NTRK inhibitor that AnHeart licensed from Daiichi Sankyo. The drug inhibits both ROS1 wild-type and major crizotinib-resistant mutations, including G2032R. There are currently no approved drugs that are effective against resistant mutations like G2032R.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.


Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.